Remicade infusions at home: An alternative setting of infliximab therapy for patients with Crohn's disease

European Journal of Gastroenterology and Hepatology

Volumn 28, Issue 2, 2016, Pages 222-225

  Kuin, Sabine ^a   Stolte, Suzan B ^a   Van Den Brink, Gijs R ^a   Ponsioen, Cyriel Y ^a   Fockens, Paul ^a   D'Haens, Geert R ^a   Löwenberg, Mark ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Costs; Crohn's disease; In home therapy; Infliximab; Patient satisfaction

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; CLEMASTINE; INFLIXIMAB; PREDNISOLONE; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CROHN DISEASE; DRUG COST; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HEART PALPITATION; HOME CARE; HUMAN; MAINTENANCE THERAPY; MALE; MIDDLE AGED; NAUSEA; PATIENT PARTICIPATION; PATIENT SATISFACTION; PERSONAL EXPERIENCE; PILOT STUDY; PRIORITY JOURNAL; REMISSION; SEBORRHEIC DERMATITIS; SIDE EFFECT; TREATMENT DURATION; YOUNG ADULT; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; DRUG ADMINISTRATION; ECONOMICS; HOSPITAL COST; INTRAVENOUS DRUG ADMINISTRATION; NETHERLANDS; PROGRAM EVALUATION; QUESTIONNAIRE; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; COST SAVINGS; COST-BENEFIT ANALYSIS; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; GASTROINTESTINAL AGENTS; HOME CARE SERVICES, HOSPITAL-BASED; HOSPITAL COSTS; HUMANS; INFLIXIMAB; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NETHERLANDS; PATIENT SATISFACTION; PILOT PROJECTS; PROGRAM EVALUATION; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84952629204     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000530     Document Type: Article

References (16)

1. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035.
2. Hana uer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
3. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
4. Sands BE,Anderson FH,Bernstein CN,Chey WY,Feagan BG,Fedorak RN,et al. Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 2004 350 876-885.
5. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-Analysis of placebo-controlled trials. Clin Gastroenterol Hepat ol 2008; 6:644-653.
6. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastroi ntest Endosc 2006; 63:433-442; quiz 464.
7. Buisson A, Seigne AL, D'Huart MC, Bigard MA, Peyrin-Biroulet L. The extra burden of infliximab infusions in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19:2464-2467.
8. Corwin P, Toop L, McGeoch G, Than M, Wynn-Thomas S, Wells JE, et al. Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared wit h hospital. BMJ 2005; 330:129.
9. Richards DA, Toop LJ, Epton MJ, McGeoch GR, Town GI, Wynn-Thomas SM, et al. Home management of mild to moderately severe community-Acquired pneumonia: a randomised controlled trial. Med J Aust 2005; 183:235-238.
10. King MT, Hall J, Caleo S, Gurney HP, Harnett PR. Home or hospital? An evaluation of the costs, preferences, and outcomes of do miciliary chemotherapy. Int J Health Serv 2000; 30:557-579.
11. Remonnay R, Devaux Y, Chauvin F, Dubost E, Carrere MO. Economic evaluation of antineoplasic chemotherapy administered at home or in hospitals. Int J Technol Assess Health Care 2002; 18:508-519.
12. Corrie PG, Moody AM, Armstrong G, Nolasco S, Lao-Sirieix SH, Bavister L, et al. Is community treatment best? a ran domised trial comparing delivery of cancer treatment in the hospital, home and GP surgery. Br J Cancer 2013; 109:1549-1555.
13. Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs 2006; 15:330-333.
14. Smid BE, Hoogendijk SL, Wijburg FA, Hollak CE, Linthorst GE. A revised home treatment algorithm for F abry disease: influence of antibody formation. Mol Genet Metab 2013; 108:132-137.
15. Condino AA, Fidanza S, Hoffenberg EJ. A home infliximab infusion program. J Pediatr Gastroenterol Nutr 2005; 40:67-69.
16. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1:514.